Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8345)	1/17/1999 11:16:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegeen, it is possible that efficacy could be demonstrated before the specified number of deaths was reached. But the company is still blinded to the results. If a company had been told by the FDA, in the interest of getting the drug to market, we will, evaluate the results even though there only a small number of accruals once X number of deaths occur. Would that company, stop the trial, before the number was reached, not knowing the results? I think something like this happened. Perhaps in time we will learn more of what really did happen. The important point, for me, at least is an understanding that the continuation of the trial is not proof of weak efficacy. That is important, to me.